KLRS (Kalaris Therapeutics) OCF Margin %: 0.00% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KLRS Kalaris Therapeutics Inc KLRS
12 GF Score
Price $3.97
View Full Analysis

What is Kalaris Therapeutics OCF Margin %?

Kalaris Therapeutics KLRS +0.76% 12 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates KLRS with a GF Score™ of 12/100. Among 953 Biotechnology companies, Kalaris Therapeutics ranks worse than 104931.69% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Kalaris Therapeutics's Cash Flow from Operations for the three months ended in Mar. 2026 was $-11.58 Mil. Kalaris Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Kalaris Therapeutics's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Kalaris Therapeutics's current OCF Yield % is -45.00%.

The historical rank and industry rank for Kalaris Therapeutics's OCF Margin % or its related term are showing as below:


KLRS's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -66.92
* Ranked among companies with meaningful OCF Margin % only.

Kalaris Therapeutics OCF Margin % Related Terms

Kalaris Therapeutics OCF Margin % Historical Data

* Premium members only.

The historical data trend for Kalaris Therapeutics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kalaris Therapeutics OCF Margin % Chart

Kalaris Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
OCF Margin %
0.00 0.00 0.00 0.00

Kalaris Therapeutics Quarterly Data
Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
KLRS
12GF Score
Kalaris Therapeutics Inc KLRS
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kalaris Therapeutics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Kalaris Therapeutics's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-38.37/0
= %

Kalaris Therapeutics's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-11.581/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Kalaris Therapeutics (KLRS) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Kalaris Therapeutics and its competitors. According to the industry distribution chart, Kalaris Therapeutics ranks #999999 out of 953 companies in the Biotechnology industry.
Is Kalaris Therapeutics' OCF Margin % too high?
Kalaris Therapeutics' current OCF Margin % is 0.00%. Based on the distribution chart, Kalaris Therapeutics ranks #999999 out of 953 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Kalaris Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Kalaris Therapeutics' OCF Margin % compare to HRTX and VRCA?
According to the Biotechnology industry distribution chart, Kalaris Therapeutics ranks #999999 out of 953 companies for OCF Margin %. This places Kalaris Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Kalaris Therapeutics and its competitors. Kalaris Therapeutics's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kalaris Therapeutics stock overvalued right now?
Kalaris Therapeutics (KLRS) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Kalaris Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Kalaris Therapeutics (KLRS), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kalaris Therapeutics Business Description

Address 400 Connell Drive, Suite 5500, Berkeley Heights, NJ, USA, 07922
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
12GF Score

Get the complete analysis for KLRS

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.97
Price